investiment.io
Shattuck Labs, Inc.
$1.54
0.07 (4.76%)
Shattuck Labs, Inc.
$1.54
0.07 (4.76%)
STTK Price Chart
| Basic | |
|---|---|
| Market Cap | $177.55M |
| Price | $1.54 |
| 52 Week Range | 1.33-11.76 |
| Beta | 1.74 |
| Margins | |
| Gross Profit Margin | 4.53% |
| Operating Profit Margin | -2195.81% |
| Net Profit Margin | -2067.99% |
| Valuation (TTM) | |
| P/E Ratio | -0.92 |
| Price to Sales Ratio | 17.82 |
| Price to Book Ratio | 0.71 |
| PEG Ratio | -0.22 |
Industry
Biotechnology
Sector
Healthcare
Full-Time Employees
75
Website
IPO Date
2020-10-09T00:00:00.000Z
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Phone
512 900 4690
Address
500 West 5th Street, Austin, TX, 78703, US
CIK
0001680367